TY  - JOUR
AU  - Reinhard, Sören
AU  - Utikal, Jochen Sven
AU  - Zaremba, Anne
AU  - Lodde, Georg
AU  - von Wasielewski, Imke
AU  - Klespe, Kai Christian
AU  - Meier, Friedegund
AU  - Haferkamp, Sebastian
AU  - Kähler, Katharina C
AU  - Herbst, Rudolf
AU  - Gebhardt, Christoffer
AU  - Sindrilaru, Anca
AU  - Dippel, Edgar
AU  - Angela, Yenny
AU  - Mohr, Peter
AU  - Pfoehler, Claudia
AU  - Forschner, Andrea
AU  - Kaatz, Martin
AU  - Schell, Beatrice
AU  - Gesierich, Anja
AU  - Loquai, Carmen
AU  - Hassel, Jessica C
AU  - Ulrich, Jens
AU  - Meiss, Frank
AU  - Schley, Gaston
AU  - Heinzerling, Lucie M
AU  - Sachse, Michael
AU  - Welzel, Julia
AU  - Weishaupt, Carsten
AU  - Sunderkötter, Cord
AU  - Michl, Christiane
AU  - Lindhof, Harm-Henning
AU  - Kreuter, Alexander
AU  - Heppt, Markus V
AU  - Wenk, Saskia
AU  - Mauch, Cornelia
AU  - Berking, Carola
AU  - Nedwed, Annekathrin Silvia
AU  - Gutzmer, Ralf
AU  - Leiter, Ulrike
AU  - Schadendorf, Dirk
AU  - Ugurel, Selma
AU  - Weichenthal, Michael
AU  - Haist, Maximilian
AU  - Fleischer, Maria Isabel
AU  - Lang, Berenice
AU  - Grabbe, Stephan
AU  - Stege, Henner
TI  - First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG.
JO  - European journal of cancer
VL  - 220
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-00614
SP  - 115356
PY  - 2025
AB  - Melanoma is the main cause of skin cancer-related death. Treatment with immune checkpoint inhibitors (CPI) has improved the prognosis in recent years. However, subtypes of melanoma differ in their response. Acral lentiginous melanoma (ALM) has a worse prognosis compared to cutaneous melanoma other than ALM (CM) and is therefore of particular relevance.To evaluate the efficacy of CPI in first-line treatment of patients with advanced ALM compared CM.Retrospective analysis of patients with metastatic ALM (n = 45) or CM (n = 328) who received first-line CPI therapy from the multicenter prospective skin cancer registry ADOREG. Study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS).ALM patients had significantly higher rates of ulcerated tumors, loco regional metastases and fewer BRAF-mutated tumors compared to CM patients. Combined CPI was administered in 48.9 
KW  - Checkpoint inhibition (Other)
KW  - Melanoma (Other)
KW  - Response (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40121837
DO  - DOI:10.1016/j.ejca.2025.115356
UR  - https://inrepo02.dkfz.de/record/300116
ER  -